Highest-materiality recent filing
Femasys stockholders elect two Class II directors and ratify KPMG as auditor
Annual meeting held June 24, 2026; 49.26% of outstanding shares represented.
Femasys regains compliance with Nasdaq minimum bid price rule after reverse stock split
Received formal notice on June 23, 2026 from Nasdaq confirming compliance with minimum bid price rule (Rule 5550(a)(2)) and matter closed.
Femasys effectuates 1-for-20 reverse stock split effective June 5, 2026
1-for-20 reverse split effective at 8:40 a.m. ET on June 5, 2026; fractional shares rounded up at DTC level.
Femasys announces 1-for-20 reverse stock split effective June 5, 2026
Effective 4:30 p.m. ET on June 5, 2026; split-adjusted trading starts June 8, 2026.
Femasys posts updated investor presentation; no material new disclosures
Slide deck highlights Femasys's reproductive health products and pipeline.
Femasys reports Q1 net income of $846K; sales up 24.5%; cash sufficient into Q3 2026
Net income $846,100 ($0.00 per diluted share) vs net loss $5.9M ($0.23 loss) in prior year; net income includes $5.2M in gains from fair value changes.
Femasys shareholders approve reverse stock split (1:2 to 1:25) and anti-dilution share issuance
Reverse split authorized by board at ratio of 1-for-2 to 1-for-25, with discretion until May 1, 2027; votes: 18.9M For, 5.2M Against.
Femasys appoints John Canning as COO; base $450K, inducement option 150K shares
John Canning appointed COO effective March 30, 2026; annual base salary $450,000 with 40% target bonus.
Femasys reports 2025 revenue up 40.8% to $2.3M; net loss $18.6M; cash into Q3 2026
Revenue increased 40.8% to $2,293,313 in 2025 from $1,629,108 in 2024, driven by FemBloc sales.
Omnibus Amendment removes Share Combination Event Adjustment from $10.5M+ senior secured convertible notes and warrants, effective Dec 31, 2025.
Femasys granted 180-day extension to cure Nasdaq minimum bid price deficiency
Received Nasdaq deficiency notice July 16, 2025; bid price below $1.00 for 30 consecutive days.
Femasys files prospectus for ATM offering of up to $9.8M common stock
Prospectus supplement filed Dec 23, 2025 for sale of up to $9.8M in common stock under existing equity distribution agreement.
Femasys receives FDA 510(k) clearance for next-gen FemVue Controlled device
FDA 510(k) clearance for FemVue Controlled, integrating FemVue and FemChec technologies.
Net loss $4.19M ($0.10/sh) vs $5.41M ($0.24/sh) a year ago on lower R&D spend.
Femasys receives second $500k FemBloc order from Kebomed for Europe
Order valued at ~$500k for commercial launch of FemBloc in France and Benelux region.
Femasys raises $12M via senior secured convertible notes and warrants
Senior secured convertible notes: $12M aggregate principal, 8.5% interest (PIK), conversion price $0.73 (15% premium to close), 10-year maturity.
Femasys gets FDA IDE approval for FemBloc final trial phase, secures $12M financing
FDA IDE approval to continue enrollment in Part B of FINALE pivotal trial for FemBloc non-surgical permanent birth control.
Femasys updates Nasdaq compliance; pro forma equity ~$5.2M meets $2.5M minimum
Received prior Nasdaq deficiency notice for MVLS below $35M and failure to meet alternative listing standards.
Femasys COO Daniel Currie to retire effective Dec 15, 2025; equity awards vest through retirement
Daniel Currie, COO since March 2004, retiring effective Dec 15, 2025 for personal health reasons.
Femasys announces $8.0M public offering of common stock and warrants
Underwritten public offering of 10,434,586 shares of common stock, pre-funded warrants for 11,750,000 shares, and common warrants for 22,184,586 shares at combined price $0.36 per unit.
Femasys secures UK MHRA approval for FemBloc permanent birth control
MHRA approval validates safety, quality, and effectiveness for UK market.
Femasys Q2 2025 sales up 85% to $409K, net loss $4.6M, cash runway into early Q4
Sales $409,268 (+84.8% YoY); net loss $4.59M ($0.16/sh) vs $4.68M ($0.21/sh) prior year.
Femasys secures first European order for FemBloc in Spain, approximately $400,000
First commercial European order for FemBloc permanent birth control valued at ~$400,000 USD.
Femasys receives Nasdaq minimum bid price non-compliance notice; 180-day cure period
Nasdaq notified Femasys on July 16, 2025, of non-compliance with $1.00 minimum bid price for 30 consecutive business days.
Femasys enters $10M equity purchase agreement with Alumni Capital LP
Up to $10M of common stock may be sold to Alumni Capital at Company's election through Dec. 31, 2026.
Femasys gets Australian & New Zealand approvals for FemaSeed and FemVue
Regulatory approvals granted for FemaSeed first-line intratubal insemination treatment and FemVue diagnostic.
CE mark certification for entire FemBloc System under EU MDR 2017/745; can now be marketed in European Economic Area (27 EU + 3 EFTA states).
Femasys stockholders elect directors, approve equity plan amendment, ratify auditor
Alistair Milnes elected with 4,882,989 votes for; Edward Uzialko with 4,947,997 votes for.
Femasys appoints Kelley Nicholas as CCO; grants 100,000-share inducement option
Appointed Kelley Nicholas as Chief Commercial Officer effective June 17, 2025; she will lead U.S. commercialization and global partnerships.
Femasys raises $4.5M in combined underwritten public offering and concurrent private placement
Underwritten public offering of 3.6M shares at $0.85/share; underwriter granted 30-day option for 540k additional shares.
Femasys receives Nasdaq delisting notice for MVLS below $35M; 180-day cure period until Nov 2025
Nasdaq notified Femasys MVLS of common stock was below $35M minimum for 30 consecutive business days.
Femasys Q1 sales up 25.9% but net loss widens to $5.9M; cash runway only into early Q3 2025
Sales increased 25.9% YoY to $341K, driven by FemaSeed sales.
Femasys reports 52% revenue growth in 2024; net loss widens to $18.8M; cash runway into Q3 2025
Revenue $1.63M, up 52% YoY; net loss $18.8M ($0.85/sh) vs $14.2M ($0.93/sh) in 2023.
Femasys secures first EU distribution partners in Spain for FemBloc birth control
Partners are Comercial Medico Quirurigca (northern Spain) and Durgalab (southern Spain).
Femasys gets CE mark for FemBloc delivery system in Europe, polymer approval expected mid-2025
FemBloc delivery system receives first-in-world CE mark certification under EU MDR for non-surgical permanent birth control.
Femasys Q3 2024 revenue up 127% to $555K; net loss widens to $5.4M
Revenue $554,908 (+127% YoY); first U.S. and international FemaSeed sales recorded.
Femasys Q3 2024 revenue up 127% to $555K; net loss widens to $5.4M
Revenue $554,908 (+127% YoY); first U.S. and international FemaSeed sales in Q3.
Femasys posts updated October 2024 investor presentation; no financial updates disclosed
Company made updated slide presentation available on its website for use in meetings with investors and analysts.
Femasys secures Spain distribution deals with $1.3M minimum FemaSeed purchase
Partners CMQ (northern Spain) and Durgalab (southern Spain) to distribute FemaSeed and FemVue.
Femasys receives FDA 510(k) clearance for FemChec fallopian tube diagnostic
FemChec cleared by FDA for controlled contrast delivery to check tubal status.
Femasys posts updated investor presentation; no material news disclosed
Company posted an updated slide presentation on its website for use in meetings with investors and analysts.
Femasys receives CE Mark and Health Canada approval for FemVue MINI fallopian tube assessment
CE Mark certification obtained for FemVue MINI, enabling sales in European Economic Area.
Femasys Q2 2024 revenue down 31% YoY to $221K; net loss widens to $4.7M
Q2 2024 sales of $221,484, down 31% from $320,514 in Q2 2023.
Femasys annual meeting elects Kathy Lee-Sepsick as Class III director, ratifies KPMG
Kathy Lee-Sepsick elected as Class III director with 3,943,064 votes for, 589,253 against, 71,779 abstained, and 6,099,540 broker non-votes.
Femasys receives CE Mark for four women's health products, enters EU market
Received EU MDR certificate and CE Mark for FemaSeed, FemVue, FemCerv, FemCath.
Femasys Q1 net loss widens to $3.6M; sales down 8%; cash runway into H2 2025
Net loss of $3.6M ($0.17 EPS) vs $2.9M ($0.25 EPS) in Q1 2023; sales $271K vs $294K.
Femasys posts updated corporate presentation on investor website
Presentation available on company website for use in investor meetings.
Femasys FY23 net loss $14.25M, sales down 11%; FemaSeed FDA clearance and positive trial data
Net loss $14.25M ($0.93/share) vs $11.39M ($0.96/share) in FY22; sales $1.07M (-11% YoY).
Pivotal trial: 24% of women became pregnant after FemaSeed in severe male factor (TMSC 1M-20M), vs 6.7% per cycle for IUI in literature.
Femasys completes first in-office commercial FemaSeed infertility procedure
First commercial procedure using FDA-cleared FemaSeed intratubal insemination performed in Saginaw, Michigan.
the Board of Directors (the “Board”) of Femasys Inc. (the “Company”) appointed Joshua Silverman as director of the Company effective November 21, 2023.
On November 8, 2023, Keith Kendall, Anne Morrissey and Wendy Perrow informed the Board of their respective resignations as a director of the Company, effective as of that date.
On November 8, 2023, Keith Kendall, Anne Morrissey and Wendy Perrow informed the Board of their respective resignations as a director of the Company, effective as of that date.
On November 8, 2023, Keith Kendall, Anne Morrissey and Wendy Perrow informed the Board of their respective resignations as a director of the Company, effective as of that date.
On August 10, 2023, the Company announced that it has designated Daniel Currie, the Company’s Senior Vice President, as its Chief Operating Officer.
Effective June 14, 2023, the Board of Directors of Femasys Inc. (the “Company”) accepted John Dyett and John Adams’s resignation from the Board of Directors.
In connection with Messrs. Dyett and Adams’s resignations, the Board of Directors appointed Keith J. Kendall and Alistair Milnes as directors of the Company.
In connection with Messrs. Dyett and Adams’s resignations, the Board of Directors appointed Keith J. Kendall and Alistair Milnes as directors of the Company.
Effective June 14, 2023, the Board of Directors of Femasys Inc. (the “Company”) accepted John Dyett and John Adams’s resignation from the Board of Directors.
On February 24, 2022, Femasys Inc. (the “ Company ”) announced the hiring and appointment of Dov Elefant as its Chief Financial Officer, effective February 28, 2022.
Effective January 19, 2022, the Board of Directors of Femasys Inc. (the “Company”) accepted William Witte’s resignation from the Board of Directors.
the Board of Directors elected Wendy Perrow as a director of the Company.
Max materiality 0.85 · Median 0.60 · Most common event other_material